Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry

Sylvia Haas, Hugo ten Cate, Gabriele Accetta, Pantep Angchaisuksiri, Jean-Pierre Bassand, A. John Camm, Ramon Corbalan, Harald Darius, David A. Fitzmaurice, Samuel Z. Goldhaber, Shinya Goto, Barry Jacobson, Gloria Kayani, Lorenzo G. Mantovani, Frank Misselwitz, Karen Pieper, Sebastian M. Schellong, Janina Stepinska, Alexander G. G. Turpie, Martin van EickelsAjay K. Kakkar

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numbere0164076
JournalPLOS ONE
Volume11
Issue number10
DOIs
Publication statusPublished - 28 Oct 2016

Cite this

Haas, S., ten Cate, H., Accetta, G., Angchaisuksiri, P., Bassand, J-P., Camm, A. J., Corbalan, R., Darius, H., Fitzmaurice, D. A., Goldhaber, S. Z., Goto, S., Jacobson, B., Kayani, G., Mantovani, L. G., Misselwitz, F., Pieper, K., Schellong, S. M., Stepinska, J., Turpie, A. G. G., ... Kakkar, A. K. (2016). Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLOS ONE, 11(10), [e0164076]. https://doi.org/10.1371/journal.pone.0164076